AB Science has announced a slight delay in the publication of its 2025 half-year financial report. Originally scheduled for September 30, the report will now be published on October 10, 2025, at the latest. The delay is to allow auditors more time to complete their audit work. AB Science focuses on developing protein kinase inhibitors for diseases with high unmet medical needs. The company’s lead compound, masitinib, is being developed for various medical conditions. AB Science is based in Paris, France, and listed on Euronext Paris. Investors are cautioned about forward-looking statements in the press release, as results may differ due to risks and uncertainties. Contact AB Science for more information.

Read more at GlobeNewswire: AB Science announces a slight delay in the publication of